Tricuspid regurgitation (TR) is a life-threatening condition that can lead to heart failure, end-organ damage such as liver failure, repeated hospitalizations, and death. Many millions suffer from moderate or severe TR, and the three-year survival rate for severe cases is less than 50%.
The Coramaze TriPair System brings healing to patients without access to alternative therapies.
Designed for effortless
Streamlined procedural steps leveraging standard catheterization techniques
Fluoro-based deployment with fast
Straightforward procedure with device time less than 20 minutes
No anesthesia and no TEE, ensuring high turn-around time in the cathlab
Flexible inflatable spacer fills the leaflet gaps
Atraumatic and effective regardless of
Repeatable thoracic echo-based efficacy testing for optimal outcomes
Coramaze Technologies was founded in 2013 as a tech-transfer from Duisburg-Essen university. It is committed to the improvement of structural heart patients’ lives by developing accessible and effective minimally invasive treatments. Our team holds a successful record in R&D of cardiovascular devices, regulatory affairs for global markets, and multicenter clinical investigations.